User:Lisachandler/Enter your new article name here

Toca 511 & Toca FC

Toca 511, the key novel component of Tocagen's first Product Candidate (Toca 511 & Toca FC), was developed using Controlled Active Gene Transfer (CAGT) technology. The CAGT platform is a Retroviral Replicating Vector (RRV) that carries the complete complement of viral genes (gag, pol, env) which allow viral replication and subsequent delivery of a therapeutic gene throughout a tumor.

Toca 511 is intended to be used in combination with Toca FC. Toca FC is a novel extended-release tablet containing 5-FC (flucytosine).

Toca 511 & Toca FC is being investigated in a Phase I/II clinical trial for the treatment of recurrent high grade glioma (HGG) brain cancer, including glioblastoma multiforme (GBM).